ABIO
$6.49
Arca Biopharma
($.19)
(2.84%)
ABIO
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Wednesday
Aug 7
4:30 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when ABIO reports earnings?
Beat
Meet
Miss

Where is ABIO's stock price going from here?
Up
Flat
Down
Stock chart of ABIO
Analysts
Summary of analysts' recommendations for ABIO
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products. The Company's business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.
Peers
Myriad GeneticsQuidelImmunomedicsCareDxMeridian BioscienceSurModics